Nationwide Fund Advisors’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-15,213
| Closed | -$330K | – | 3236 |
|
|
2017
Q2 | $330K | Hold |
15,213
| – | – | ﹤0.01% | 2396 |
|
|
2017
Q1 | $213K | Sell |
15,213
-1,237
| -8% | -$20.3K | ﹤0.01% | 2553 |
|
|
2016
Q4 | $309K | Hold |
16,450
| – | – | ﹤0.01% | 2419 |
|
|
2016
Q3 | $272K | Hold |
16,450
| – | – | ﹤0.01% | 2477 |
|
|
2016
Q2 | $221K | Buy |
16,450
+743
| +5% | +$10.8K | ﹤0.01% | 2561 |
|
|
2016
Q1 | $240K | Sell |
15,707
-689
| -4% | -$10.8K | ﹤0.01% | 2449 |
|
|
2015
Q4 | $325K | Buy |
16,396
+291
| +2% | +$5.53K | ﹤0.01% | 2315 |
|
|
2015
Q3 | $281K | Hold |
16,105
| – | – | ﹤0.01% | 2399 |
|
|
2015
Q2 | $326K | Sell |
16,105
-4,127
| -20% | -$79.6K | ﹤0.01% | 2473 |
|
|
2015
Q1 | $356K | Sell |
20,232
-547
| -3% | -$9.32K | ﹤0.01% | 2419 |
|
|
2014
Q4 | $338K | Sell |
20,779
-28,004
| -57% | -$514K | ﹤0.01% | 2399 |
|
|
2014
Q3 | $1.08M | Buy |
48,783
+4,263
| +10% | +$87.3K | ﹤0.01% | 1785 |
|
|
2014
Q2 | $896K | Buy |
+44,520
| New | +$754K | ﹤0.01% | 1929 |
|
|
2014
Q1 | – | Sell |
-22,160
| Closed | -$223K | – | 3263 |
|
|
2013
Q4 | $223K | Sell |
22,160
-475
| -2% | -$5.74K | ﹤0.01% | 2638 |
|
|
2013
Q3 | $292K | Buy |
22,635
+11,096
| +96% | +$136K | ﹤0.01% | 2483 |
|
|
2013
Q2 | $137K | Buy |
+11,539
| New | +$125K | ﹤0.01% | 2668 |
|
Other funds holding AMRI
Nationwide Fund Advisors's AMRI Position: Q3 2017 in Review
Nationwide Fund Advisors sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 15,213 shares — an estimated $330K sold.
Nationwide Fund Advisors first reported a position in AMRI in Q2 2013 and held it in 16 quarters. The position peaked at $1.08M in Q3 2014. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Nationwide Fund Advisors reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Nationwide Fund Advisors sold 15,213 Albany Molecular Research Inc shares in Q3 2017, an estimated $330K.
- Nationwide Fund Advisors first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 16 quarters.
- Nationwide Fund Advisors's Albany Molecular Research Inc position peaked at $1.08M in Q3 2014.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Nationwide Fund Advisors's 13F filing for Q3 2017, filed 23 Oct 2017.